RCS - Creo Medical Group - First Welsh adopter of Speedboat® technology

Creo MedicalAnnouncement

06/02/2025 09:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250206:nRSF1784Wa&default-theme=true

RNS Number : 1784W  Creo Medical Group PLC  06 February 2025

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

First Welsh adopter of Speedboat® technology for colon cancer

 

Aneurin Bevan University Health Board initiates Speedboat® pilot

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the
emerging field of minimally invasive surgical endoscopy for pre-cancer and
cancer patients, announces that the Aneurin Bevan University Health Board
("ABUHB") has initiated a six-month pilot of Creo's Speedboat® technology,
becoming the first Health Board in Wales to implement the technology.

 

The news has been announced by ABUHB online and is available to view via the
following link.

 

https://abuhb.nhs.wales/news/news/aneurin-bevan-university-health-board-leads-the-way-in-wales-with-innovative-speedboat-device-to-tackle-colon-cancer/
(https://abuhb.nhs.wales/news/news/aneurin-bevan-university-health-board-leads-the-way-in-wales-with-innovative-speedboat-device-to-tackle-colon-cancer/)

 

The full text is reproduced below:

 

Aneurin Bevan University Health Board Leads the Way in Wales

with Innovative Speedboat Device to Tackle Colon Cancer

 

Aneurin Bevan University Health Board (ABUHB) has become the first in Wales to
pilot the groundbreaking Speedboat Submucosal Dissection (SSD) technology,
transforming the treatment pathway for patients with complex colorectal
polyps. Developed by Welsh med-tech company Creo Medical, this innovative
device offers a minimally invasive alternative to traditional surgery,
significantly improving patient outcomes and recovery times.

 

Currently, patients with complex polyps often face multiple procedures or
major surgery, which can result in lengthy recovery times and higher risks.
The Speedboat device allows clinicians to perform a single, minimally invasive
procedure to remove polyps effectively, reducing the need for surgery and
enabling faster patient recovery. Introducing this technology addresses a
critical gap in treatment services in Wales.

 

Dr. Alka Joshi, Clinical Lead for the pilot, commented: "This pilot is a
significant step forward for our patients. By utilising the Speedboat device,
we can offer a more efficient, less invasive alternative to traditional
surgical methods, improving outcomes and reducing waiting times."

 

Since the pilot's launch before Christmas, three patients have undergone the
treatment successfully with no recorded complications. Each procedure was
completed in a single session, and all patients were discharged the same day.
One patient even resumed normal activities, including Christmas shopping, the
very next day.

 

Backed by the Health Board's Clinical Safety and Effectiveness Group, the
pilot is supported by Creo's on-site clinical education program, which reduces
clinician training time from years to just months. This mentorship model
enables ABUHB to embed the procedure at pace while ensuring safety and
cost-effectiveness, creating a potential replicable blueprint for adoption
across other health boards in Wales.

 

Rob Holcombe, Finance Director & Innovation Executive Lead at ABUHB,
stated: "We are proud to champion this innovative Welsh technology in ABUHB.
The early success of this pilot highlights the Board's commitment to
delivering solutions that enhance patient care, reduce pressure on surgical
services and demonstrate ABUHB's approach to adopting medical innovation
through 'value- based health care' outcome evaluation."

 

The ABUHB video can be viewed here: https://vimeo.com/1053790954
(https://vimeo.com/1053790954)

 

Craig Gulliford, Chief Executive Officer of Creo, said: "As a Welsh company,
it is exciting that the Aneurin Bevan team are the first in Wales to use our
Speedboat for the benefit of its colon cancer patients; the SSD pilot in could
enhance patient outcomes, reduce surgical waiting lists, and facilitate the
wider adoption of this technique across other Health Boards in Wales."

 

 

For further information please contact:

 

 Creo Medical Group plc                                                  www.creomedical.com
                                                                         (https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)
 Richard Craven, Company Secretary                                       Via Walbrook PR

 Cavendish Capital Markets Limited

 (Nominated Adviser and Joint Broker)                                    +44 (0)20 7220 0500
 Stephen Keys / Camilla Hume / George Lawson (NOMAD)
 Michael Johnson (Sales)

 Deutsche Numis (Joint Broker)                                           +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR Ltd                Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings  Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 Phillip Marriage               Mob: +44 (0)7867 984 082

 

 

About Creo Medical

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPKABPFBKKABK